Интересные новости о недавно обсуждаемом.

[Yariko]

Сообщение от Gilarov

Я бы пока не был столь оптимистичен, ибо речь идет о ретроспективном исследовании и от назначения бета-блоков всем пациентам с ХОБЛ воздержался.).

соглашусь

Сообщение от Gilarov

верно лишь в отношении cardiac drugs, т. к., что, конечно же не может полностью говорить о тяжести сопутствующей кардиальной патологии.

не соглашусь

Through matched propensity scoring analysis, our data suggest a 22% overall reduction in all cause mortality for patients with COPD when their inhaled treatment regimen includes β blockers. Importantly, our data also suggest there may be benefits when β blockers. Our Cox proportional hazard regression analyses
have shown that the additive benefits of β blockers were independent of other cardiovascular drugs and history of overt cardiovascular disease (ischaemic heart disease, heart failure, peripheral vascular disease). These findings suggest that β blockers have effects on reducing mortality in COPD in addition to the benefits gained by reducing cardiovascular risk.

We evaluated the effects of β blockers on all cause mortality independently of cardiovascular outcomes, including cardiac drug prescription and overt cardiovascular disease as measured by hospital admissions due to ischaemic heart disease, heart failure, or peripheral vascular disease (although a history of hypertension was unavailable for analysis from our database). Furthermore, when assessing the impact of β blocker use on all cause mortality, we performed a matched propensity scoring analysis, which is designed to minimise the effects of confounding by indication.

Сообщение от Gilarov

Хотя, бета-блокеры, наверное могут устранять негативные последствия использования бета-агонистов и в этом причина их эффекта при ХОБЛ (88% бета-блокеров были кардиосерективными).

да, вероятно

One possibility is that up-regulation of β2 adrenoceptors by chronic β blockade may improve the effectiveness of β2 agonists. Despite most of the β blockers in our study being relatively cardioselective, drugs such as atenolol and bisoprolol have been shown to exert significant β2 adrenoceptor antagonism even at therapeutic doses, which may result in β2
adrenoceptor up-regulation. Thus, up-regulation of β2 adrenoceptors by cardioselective β blockers seems plausible.